Back to results
US 2023/0417741 A1Published application
Nanoparticle-enabled analysis of cell-free nucleic acid in complex biological fluids
AssigneeThe University of Manchester
InventorsMarilena HADJIDEMETRIOU, Kostas KOSTARELOS, Lois GARDNER
Life of this patent
Estimating the term…
Abstract
The invention relates to methods for capturing, quantifying and analyzing cell free nucleic acid (cfNA) in biofluid samples, such as blood and urine.
Claims24
A method of identifying cell free nucleic acid (cfNA) in a biofluid, wherein the method comprises:
- (a) contacting a plurality of nanoparticles with a biofluid of a subject to allow a biomolecule corona to form on the surface of said nanoparticles;
- (b) isolating the nanoparticles and surface-bound biomolecule corona;
- and
- (c) analyzing the biomolecule corona for cfNA.
1 more element
(canceled)
(canceled)
(canceled)
(canceled)
A method for detecting a disease state in a subject comprising:
- (a) contacting a biofluid sample from the subject with a plurality of nanoparticles under conditions to allow a biomolecule corona to form on the surface of said nanoparticles;
- (b) isolating the nanoparticles and surface-bound biomolecule corona;
- and
- (c) analyzing the biomolecule corona for a disease-specific cfNA biomarker, which is determinative of the presence of a disease in said subject.
1 more element
A method for diagnosing cancer in a subject, comprising:
- (a) contacting a biofluid sample from the subject with a plurality of nanoparticles under conditions to allow a biomolecule corona to form on the surface of said nanoparticles;
- (b) isolating the nanoparticles and surface-bound biomolecule corona;
- and
- (c) analyzing the biomolecule corona for cfNA;
- wherein an increase in total cfNA level relative to a reference or control amount is indicative of the presence of cancer.
2 more elements
A method for monitoring disease progression in a subject, comprising:
- (a) contacting a biofluid sample from the subject with a plurality of nanoparticles under conditions to allow a biomolecule corona to form on the surface of said nanoparticles;
- (b) isolating the nanoparticles and surface-bound biomolecule corona;
- and
- (c) analyzing the biomolecule corona for cfNA;
- wherein the degree of disease progression is determined based on the total cfNA level or cfNA level of a disease-specific biomarker relative to a reference amount,
- optionally wherein the reference amount is the amount detected at a previous time point.
3 more elements
Dependencies are inferred from the claim text.